Registro delle gravidanze Kesimpta (Ofatumumab).
Studio sulla sicurezza post-autorizzazione per la valutazione della gravidanza e degli esiti infantili nei pazienti trattati con Kesimpta (Ofatumumab) utilizzando il programma di sorveglianza osservazionale della gravidanza OTIS e il registro DMSKW
The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The study is expected to enroll for approximately 7 years and follow the pregnant women and their infant(s) over a maximum of 21 months.
The study will be conducted as two sub-studies leveraging independent ongoing pregnancy registries:
- The Organization of Teratology Information Specialists (OTIS) Research Group, University of California, San Diego, USA (referred to as "OTIS") will serve as data source for the Kesimpta-OTIS sub-study;
- The German MS and pregnancy registry - Deutschsprachigen Multiple Sklerose und Kinderwunsch Register (DMSKW) at Katholisches Klinikum Bochum gGmbH, St Josef Hospital, Bochum, Germany (referred to as "DMSKW") will serve as data source for the Kesimpta- DMSKW sub-study.
Both registries will independently collect and assess data related to the pregnancy and infant outcomes of interest and provide aggregate data which will be further combined (metaanalyses) by Novartis (referred to as the Sponsor) or a designated contract research organization (CRO).
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Novartis Pharmaceuticals
- Numero di telefono: 1-888-669-6682
- Email: novartis.email@novartis.com
Backup dei contatti dello studio
- Nome: Novartis Pharmaceuticals
- Numero di telefono: +41613241111
- Email: mothertobaby@health.ucsd.edu
Luoghi di studio
-
-
California
-
La Jolla, California, Stati Uniti, 92093-0934
- Reclutamento
- University of California San Diego OTIS
-
Contatto:
- Numero di telefono: 877-311-8972
-
Investigatore principale:
- Christina Chambers
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Participants from sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively.
Descrizione
Inclusion Criteria:
Participants must meet all the criteria listed under the respective cohorts to enroll in that particular cohort of the registry:
Cohort 1: Kesimpta-Exposed Cohort
- Pregnant women
- Diagnosed with MS, with the indication validated by medical records when possible
- Administered Kesimpta for the treatment of MS at any time from 166 days prior to the first day of the LMP, or up to and including the end of pregnancy
- Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants (OTIS specific), and validated developmental performance questionnaire in live born children
Cohort 2: Disease-Matched Comparison Cohort (Comparison Group 1)
- Pregnant women
- Diagnosed with MS, with the indication validated by medical records when possible
- May or may not have taken another medication for MS in the current pregnancy
- Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants (OTIS specific), and validated developmental performance questionnaire in live born children
Cohort 3: Healthy Comparison Cohort (Comparison Group 2):Kesimpta-OTIS sub-study specific
- Pregnant women
- Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants, and validated developmental performance questionnaire in live born children
Exclusion Criteria:
Women meeting any of the following criteria will be excluded from the cohort study:
Cohort 1: Kesimpta-Exposed Cohort
-
Women who have enrolled in the Kesimpta cohort study with a previous pregnancy
-
Women who have used Kesimpta for an indication other than a currently approved indication
-
Women with exposure to any of the following medications within 5 half-lives (or pharmacodynamic effect when relevant) prior to conception:
- Other anti-CD20 monoclonal antibody: same class as Kesimpta
- S1P modulators: same class as Mayzent
- Cladribine (Mavenclad): Based on the US label, animal studies indicate that there is positive evidence of teratogenicity for Cladribine
- Teriflunomide (Aubagio): The teratogenecity of teriflunomide is unknown and currently under investigation.
- New medications (marketed after 2021) indicated for the treatment of MS will be evaluated for inclusion/exclusion criteria as the study progresses.
-
Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)
-
Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.
Cohort 2: Disease-Matched Comparison Cohort (Comparison Group 1)
-
Administered Kesimpta 166 days before the first day of LMP or anytime during pregnancy
-
Women with exposure to any of the following medications within 5 half-lives (or pharmacodynamic effect when relevant) of conception:
- Anti CD-20 monoclonal antibody
- Cladribine (Mavenclad)
- S1P modulators
- Teriflunomide (Aubagio) New medications (marketed after 2021) indicated for the treatment of MS will be evaluated for inclusion/exclusion criteria as the study progresses.
-
Women who have enrolled in the Kesimpta cohort or BAF312A2403 Mayzent cohort with a previous pregnancy
-
Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)
-
Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.
Cohort 3: Healthy Comparison Cohort (Comparison Group 2): Only applicable to Kesimpta-OTIS sub-study
- Administered Kesimpta 166 days before or Mayzent 4 days after the first day of LMP or anytime during pregnancy
- Women who have a diagnosis of a MS
- Women who have a current diagnosis of any autoimmune disease
- Women who have first contact with the project after prenatal diagnosis of any major structural defect
- Women treated with Mayzent or Kesimpta for non-MS indication
- Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)
- Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.
- Women exposed to a known human teratogenic drugs during pregnancy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Disease-matched cohort (Comparison Group 1)
comparison group consisting of women diagnosed with MS who have not used Kesimpta during pregnancy (unexposed disease-matched comparison group). |
|
|
Healthy cohort (only applicable in the Kesimpta-OTIS sub-study) (Comparison Group 2)
healthy women who are not diagnosed with MS or any other autoimmune disease, have not had exposure to a known human teratogen, and have not taken Kesimpta in pregnancy (healthy comparison group). Since the DMSKW register is an MS population specific register that does not collect data on non-MS population, this cohort is only applicable in the Kesimpta-OTIS sub-study. |
|
|
Kesimpta-exposed cohort
women and infants who are exposed to Kesimpta during pregnancy to treat MS. |
Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with major structural defects
Lasso di tempo: Up to 21 months
|
Number of participants with major structural defects will be collected |
Up to 21 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with spontaneous abortion/miscarriage
Lasso di tempo: Up to 21 months
|
Number of participants with spontaneous abortion/miscarriage will be collected |
Up to 21 months
|
|
Number of stillbirth cases
Lasso di tempo: Up to 21 months
|
Number of stillbirth cases will be collected |
Up to 21 months
|
|
Number of elective termination cases
Lasso di tempo: Up to 21 months
|
Number of elective termination cases will be collected |
Up to 21 months
|
|
Number of preterm delivery cases
Lasso di tempo: Up to 21 months
|
Number of preterm delivery cases will be collected |
Up to 21 months
|
|
Number of preeclampsia / eclampsia cases
Lasso di tempo: Up to 21 months
|
Number of preeclampsia / eclampsia cases will be collected |
Up to 21 months
|
|
Number of cases with pattern of 3 or more minor structural defects
Lasso di tempo: Up to 21 months
|
Number of cases with pattern of 3 or more minor structural defects will be collected |
Up to 21 months
|
|
Number of participants small for gestational age
Lasso di tempo: Up to 21 months
|
Number of participants small for gestational age will be collected |
Up to 21 months
|
|
Number of participants with postnatal growth small for age at one year of age
Lasso di tempo: Up to 21 months
|
Number of participants with postnatal growth small for age at one year of age will be collected |
Up to 21 months
|
|
Developmental performance at approximately one year of age: Michaelis developmental milestones questionnaires
Lasso di tempo: Up to 21 months
|
The Michaelis developmental milestones questionnaires will be used to assess the developmental performance in live born infants. |
Up to 21 months
|
|
Developmental performance at approximately one year of age: Denver developmental screening test
Lasso di tempo: Up to 21 months
|
Denver developmental screening test will be used to assess the developmental performance in live born infants; |
Up to 21 months
|
|
Number of serious or opportunistic infections in the first year of life.
Lasso di tempo: Up to 21 months
|
Number of serious or opportunistic infections in the first year of life will be collected |
Up to 21 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- COMB157G2403
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .